GDF-11

Growth differentiation factor 11

Grade D: Preclinical or anecdotal only

TL;DR: GDF-11 (Growth Differentiation Factor 11) has no human clinical trials involving exogenous administration; the entire intervention evidence base is preclinical. Animal studies, primarily mouse parabiosis experiments published around 2013-2014, initially suggested GDF-11 could reverse age-related cardiac hypertrophy and support neural and vascular repair, generating significant media coverage. Those findings became scientifically contested when independent groups reported measurement artifacts and showed that high doses of GDF-11 in mice can suppress muscle regeneration and cause cachexia-like effects. A 2024 review concluded that GDF-11 does not simply decline with age and that the therapeutic window, if any, is extremely narrow. Observational human data on circulating GDF-11 levels is available but contradictory across populations. There is currently no basis to infer benefit from exogenous GDF-11 in humans.

Key Takeaways

Grade D: Preclinical or anecdotal only
Not FDA approved: No FDA approval; classified as a research compound only with no IND identified for human aging indications.
Compounding: Its federal compounding status is not separately established in the FDA bulk-substance lists we verify; confirm current status with a licensed pharmacist or physician before any use.

Mechanism

A member of the TGF-beta superfamily proposed to act as a circulating aging-related factor that modulates tissue homeostasis, though whether it acts primarily as a rejuvenating signal or an inhibitor of regeneration remains unresolved in the literature.

Evidence

GDF-11 (Growth Differentiation Factor 11) has no human clinical trials involving exogenous administration; the entire intervention evidence base is preclinical. Animal studies, primarily mouse parabiosis experiments published around 2013-2014, initially suggested GDF-11 could reverse age-related cardiac hypertrophy and support neural and vascular repair, generating significant media coverage. Those findings became scientifically contested when independent groups reported measurement artifacts and showed that high doses of GDF-11 in mice can suppress muscle regeneration and cause cachexia-like effects. A 2024 review concluded that GDF-11 does not simply decline with age and that the therapeutic window, if any, is extremely narrow. Observational human data on circulating GDF-11 levels is available but contradictory across populations. There is currently no basis to infer benefit from exogenous GDF-11 in humans.

Safety and risks

High-dose GDF-11 administration in animals has been associated with impaired muscle regeneration and weight loss; the relevance to any human dose is unknown but the signal is concerning. Animal studies have shown adverse effects on liver regeneration and hepatocellular injury at certain doses. GDF-11 belongs to the TGF-beta superfamily; systemic elevation of TGF-beta pathway ligands carries theoretical risks related to fibrosis and tumor progression. No human pharmacokinetic, pharmacodynamic, or safety data exist for exogenous GDF-11 administration. The contested state of the underlying science means the risk-benefit profile cannot be meaningfully estimated. Supply chain and purity concerns apply: GDF-11 sold outside clinical settings lacks any quality oversight.

Interactions

Unknown. TGF-beta pathway interactions are theoretically broad; no human data.

Compounding legality

Its federal compounding status is not separately established in the FDA bulk-substance lists we verify; confirm current status with a licensed pharmacist or physician before any use.

Sources

GDF-11 is Not FDA approved. PeptideGrids presents evidence and regulatory status for informational purposes only. We do not sell, supply, source, or help anyone obtain this compound, and we provide no dosing or administration guidance. This is not medical advice; consult a licensed clinician. Full disclaimer.

Last reviewed June 2, 2026 by PeptideGrids editorial team (independently audited).